← Back to Search

Enzyme Inhibitor

Salt-Sensitivity Blood Pressure Study in Healthy Subjects

Q: Is the age limit for participation in this research project restricted to those under 55 years of age?

The team conducting this research study is seeking individuals between 25 and 45 years old for participation.

Q: Is my profile compatible with the requirements for participating in this research?

To be eligible for this medical trial, participants must have a healthy body and fall between 25-45 years old. In total, the researchers are searching for 88 human volunteers.

Q: Is there still capacity for individuals to participate in this experiment?

The clinical trial that was initially posted on the 2nd of January 2017 and last revised on July 9th 2018 is not accepting applicants at present. However, there are 1072 other studies actively looking for participants right now.

N/A

Waitlist Available

Research Sponsored by Brigham and Women's Hospital

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be between 18 and 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up after 1 week dietary salt manipulation on both diets

Awards & highlights

Study Summary

This trial will study how salt affects blood pressure by looking at the salt-sensitive regulatory enzyme Lysine-specific demethylase 1.

Who is the study for?

This trial is for healthy Caucasian or African American individuals aged 25-45, with normal blood pressure and no history of major diseases like hypertension, diabetes, or heart disease. Participants must not be overweight (BMI <25), drink more than 6oz alcohol weekly, use tobacco/drugs/NSAIDs, be pregnant/breastfeeding, have certain drug sensitivities or recent steroid use.Check my eligibility

What is being tested?

The study aims to understand how dietary salt affects blood pressure regulation through the enzyme Lysine-specific demethylase 1. It will measure changes in vascular stiffness, kidney blood flow response to salt intake and aldosterone levels after Angiotensin II infusion.See study design

What are the potential side effects?

Potential side effects may include reactions to infused substances such as Angiotensin II which can cause changes in blood pressure or allergic responses. However, since this is a study on healthy subjects without underlying conditions and focuses on observation rather than treatment intervention, fewer side effects are expected.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ after 1 week dietary salt manipulation

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~after 1 week dietary salt manipulation

This trial's timeline: 3 weeks for screening, Varies for treatment, and after 1 week dietary salt manipulation for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Aldosterone response to angiotensin II

Secondary outcome measures

Renal blood flow response to dietary salt

Vascular stiffness response to angiotensin II

Trial Design

4Treatment groups

Active Control

Placebo Group

Group I: Afr-Amer risk alleleActive Control3 Interventions

African Americans carrying the LSD1 affected allele

Group II: Cauc risk allelePlacebo Group3 Interventions

Caucasians carrying the LSD1 affected allele

Group III: Cauc non-risk allelePlacebo Group3 Interventions

Caucasians carrying the LSD1 non-risk allele

Group IV: Afr-Amer non-risk allelePlacebo Group3 Interventions

African Americans carrying the LSD1 non-risk allele

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Brigham and Women's HospitalLead Sponsor

1,616 Previous Clinical Trials

11,470,860 Total Patients Enrolled

Media Library

Lysine-specific demethylase 1 inhibitor (Enzyme Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT03029806 — N/A

Healthy Subjects Research Study Groups: Afr-Amer risk allele, Cauc risk allele, Cauc non-risk allele, Afr-Amer non-risk allele

Healthy Subjects Clinical Trial 2023: Lysine-specific demethylase 1 inhibitor Highlights & Side Effects. Trial Name: NCT03029806 — N/A

Lysine-specific demethylase 1 inhibitor (Enzyme Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT03029806 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is the age limit for participation in this research project restricted to those under 55 years of age?

"The team conducting this research study is seeking individuals between 25 and 45 years old for participation."

Answered by AI

Is my profile compatible with the requirements for participating in this research?

"To be eligible for this medical trial, participants must have a healthy body and fall between 25-45 years old. In total, the researchers are searching for 88 human volunteers."

Answered by AI

Is there still capacity for individuals to participate in this experiment?

"The clinical trial that was initially posted on the 2nd of January 2017 and last revised on July 9th 2018 is not accepting applicants at present. However, there are 1072 other studies actively looking for participants right now."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Lysine-specific Demethylase 1 and Salt-sensitivity in Humans

Jonathan S. Williams, MD, MMSc 2017. "Lysine-specific Demethylase 1 and Salt-sensitivity in Humans". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03029806.